Long-acting treatments bring new hope to hemophilia patients

03/10/2014 | Reuters

Long-acting drugs for hemophilia have emerged that could reduce the need for regular intravenous infusions of blood clotting agents. Treatments such as Biogen's Alprolix and Novo Nordisk's investigational drug N9-GP could help cut the cost of existing treatments, according to industry experts. Biotech companies such as BioMarin Pharmaceutical and Sangamo BioSciences are working on gene therapies that could enable people with hemophilia to make their own clotting factor.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA